Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SSS68 Single Ascending Dose Study in Healthy Adults
NCT07606976Phase 1Not yet recruiting
- Sponsor
- 3SBio
- Start
- Jun 2026
- Primary completion
- Dec 2026
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial comparing SSS68 with Placebo (2 arms). Primary endpoint: Treatment Emergent Adverse Events. Planned start Jun 2026; status: not yet recruiting.
02
Drugs
SSS68
Beyond the preview
Go deeper on NCT07606976.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07606976.